Company / Operating Cash Flow
Corbus Pharmaceuticals Holdings, Inc. Operating Cash Flow History
FY2015-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$48.2M
FY2022
5-year range
-$99.7M / -$27.8M
FY2018-FY2022
Trend
+51.7%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow returned to growth in FY2022 after 4 years of decline, reaching -$48M.
Based on SEC 10-K filings.
-$48M in FY2022.
Declined from -$46M to -$48M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, operating cash flow increased 51.7% year-over-year.
- Peak operating cash flow was recorded in FY2015.
- Lowest operating cash flow in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -12.48 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | -$48.2M | +51.7% |
| FY2021 | -$99.7M | -118.0% |
| FY2020 | -$45.7M | -52.1% |
| FY2019 | -$30.1M | -8.2% |
| FY2018 | -$27.8M | -501.0% |
| FY2017 | -$4.6M | +0.0% |
| FY2016 | -$4.6M | -95.9% |
| FY2015 | -$2.4M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026